Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Recommendation of “Moderate Buy” by Analysts

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $2.18.

Several research analysts have commented on the stock. Mizuho dropped their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. StockNews.com assumed coverage on shares of Adaptimmune Therapeutics in a research note on Friday. They set a “buy” rating for the company. Wells Fargo & Company decreased their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday. Finally, Scotiabank cut their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research note on Friday.

Adaptimmune Therapeutics Trading Up 3.9 %

NASDAQ ADAP traded up $0.01 during trading hours on Friday, hitting $0.29. 4,999,050 shares of the company were exchanged, compared to its average volume of 1,407,286. The stock has a market cap of $74.41 million, a PE ratio of -1.32 and a beta of 2.52. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The stock has a 50-day moving average price of $0.55 and a 200 day moving average price of $0.71. Adaptimmune Therapeutics has a 52 week low of $0.26 and a 52 week high of $1.65.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in ADAP. Invesco Ltd. raised its stake in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares in the last quarter. Two Sigma Advisers LP increased its holdings in Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 58,787 shares during the period. Two Sigma Investments LP raised its position in Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 19,146 shares in the last quarter. Virtu Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 21.5% in the 4th quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after buying an additional 21,688 shares during the period. Finally, GSA Capital Partners LLP bought a new position in shares of Adaptimmune Therapeutics during the 3rd quarter worth $95,000. 31.37% of the stock is owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.